+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Rifaximin Market Outlook 2026-2034: Market Size, Share and Growth Analysis- Product Image
Rifaximin Market Outlook 2026-2034: Market Size, Share and Growth Analysis- Product Image
Sale

Rifaximin Market Outlook 2026-2034: Market Size, Share and Growth Analysis

  • PDF Icon

    Report

  • 160 Pages
  • October 2026
  • Region: Global
  • OG Analysis
  • ID: 6243540
UP TO OFF until Jan 01st 2027
Description Jump to:
The Rifaximin Market is estimated at US$2 billion in 2026 and is projected to grow at a CAGR of 10.6% to reach US$4.5 billion by 2034.

Market Overview

The Rifaximin Market covers prescription drug products centered on rifaximin use for gastrointestinal and related therapeutic applications across specialty and general care channels. Its value chain includes active pharmaceutical ingredient suppliers, formulation manufacturers, specialty distributors, pharmacies, hospitals, prescribing clinicians, and reimbursement support networks.

Core applications include hepatic encephalopathy management, traveler related gastrointestinal care, irritable bowel support, hospital prescribing, and outpatient digestive disease treatment. At the same time, suppliers must respond to pricing pressure, generic competition risk, reimbursement scrutiny, and market access barriers in cost sensitive healthcare systems.

Key Companies Analysed

  • Bausch Health
  • Salix Pharmaceuticals
  • Lupin
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Alkem Laboratories
  • Torrent Pharmaceuticals
  • Cipla
  • Aurobindo Pharma
  • Apotex
  • Amneal Pharmaceuticals
  • Sandoz
  • Zydus Lifesciences
  • Hetero
  • Alembic Pharmaceuticals
  • Macleods Pharmaceuticals
  • Beximco Pharma
  • AbbVie
  • Pfizer

Geographic Coverage

  • North America - Market data and outlook to 2034
    • United States
    • Canada
    • Mexico

  • Europe - Market data and outlook to 2034
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Netherlands
    • Switzerland
    • Poland
    • Sweden
    • Russia

  • Asia-Pacific - Market data and outlook to 2034
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Malaysia
    • Vietnam

  • Middle East and Africa - Market data and outlook to 2034
    • Saudi Arabia
    • South Africa
    • Iran
    • UAE
    • Egypt

  • South and Central America - Market data and outlook to 2034
    • Brazil
    • Argentina
    • Chile
    • Peru

*We can include data and analysis of additional countries on demand.

Report Delivery and Support

  • Updated PDF report and an MS Excel workbook containing market tables and figures.
  • 7-day post-sale analyst support for clarifications and in-scope supplementary data.
  • Complimentary report update covering the latest available data and relevant market developments.

This product will be delivered within 1-3 business days.

Table of Contents

1. Contents and Report Guide
1.1. List of Tables
1.2. List of Figures
2. Global Rifaximin Market Overview
2.1. Rifaximin Market Scope and Definitions
2.2. Research Methodology and Forecast Assumptions
2.3. Value Chain and Relevant Adjacent Markets
3. Rifaximin Market Dynamics
3.1. Demand Drivers
3.2. Constraints and Adoption Barriers
3.3. Technology and Commercial Trends
3.4. Regulatory and Supply-Chain Considerations
4. Rifaximin Market Strategic Analysis
4.1. Competitive Structure
4.2. Pricing and Purchasing Factors
4.3. Customer Requirements and Opportunity Assessment
5. Global Rifaximin Market Size, Share and Forecast, 2025-2034
5.1. Revenue Outlook, 2025-2034 (US$ billion)
6. North America Rifaximin Market Outlook to 2034
6.1. North America Market Snapshot
6.2. North America Outlook By Country
6.2.1. United States
6.2.2. Canada
6.2.3. Mexico
7. Europe Rifaximin Market Outlook to 2034
7.1. Europe Market Snapshot
7.2. Europe Outlook By Country
7.2.1. Germany
7.2.2. United Kingdom
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Netherlands
7.2.7. Switzerland
7.2.8. Poland
7.2.9. Sweden
7.2.10. Russia
8. Asia-Pacific Rifaximin Market Outlook to 2034
8.1. Asia-Pacific Market Snapshot
8.2. Asia-Pacific Outlook By Country
8.2.1. China
8.2.2. Japan
8.2.3. India
8.2.4. South Korea
8.2.5. Australia
8.2.6. Indonesia
8.2.7. Malaysia
8.2.8. Vietnam
9. Middle East and Africa Rifaximin Market Outlook to 2034
9.1. Middle East and Africa Market Snapshot
9.2. Middle East and Africa Outlook By Country
9.2.1. Saudi Arabia
9.2.2. South Africa
9.2.3. Iran
9.2.4. United Arab Emirates
9.2.5. Egypt
10. South and Central America Rifaximin Market Outlook to 2034
10.1. South and Central America Market Snapshot
10.2. South and Central America Outlook By Country
10.2.1. Brazil
10.2.2. Argentina
10.2.3. Chile
10.2.4. Peru
11. Rifaximin Market Competitive Landscape
11.1. Market Participants and Strategic Positioning
11.2. Company Profiles: Product Portfolios, Positioning and Strategies
11.2.1. Bausch Health
11.2.2. Salix Pharmaceuticals
11.2.3. Lupin
11.2.4. Sun Pharmaceutical Industries
11.2.5. Teva Pharmaceutical Industries
11.2.6. Dr. Reddy's Laboratories
11.2.7. Alkem Laboratories
11.2.8. Torrent Pharmaceuticals
11.2.9. Cipla
11.2.10. Aurobindo Pharma
11.2.11. Apotex
11.2.12. Amneal Pharmaceuticals
11.2.13. Sandoz
11.2.14. Zydus Lifesciences
11.2.15. Hetero
11.2.16. Alembic Pharmaceuticals
11.2.17. Macleods Pharmaceuticals
11.2.18. Beximco Pharma
11.2.19. AbbVie
11.2.20. Pfizer
12. Appendix
12.1. Definitions and Abbreviations
12.2. Data Sources and Methodology
12.3. Publisher Information

Companies Mentioned

  • Bausch Health
  • Salix Pharmaceuticals
  • Lupin
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Alkem Laboratories
  • Torrent Pharmaceuticals
  • Cipla
  • Aurobindo Pharma
  • Apotex
  • Amneal Pharmaceuticals
  • Sandoz
  • Zydus Lifesciences
  • Hetero
  • Alembic Pharmaceuticals
  • Macleods Pharmaceuticals
  • Beximco Pharma
  • AbbVie
  • Pfizer

Table Information

Report AttributeDetails
No. of Pages160
PublishedOctober 2026
Forecast Period2026 - 2034
Estimated Market Value in 2026 2 Billion
Forecasted Market Value by 2034 4.5 Billion
Compound Annual Growth Rate10.6%
Regions CoveredGlobal
No. of Companies Mentioned20

Related Topics

Related Reports

Rifaximin Capsules Market - Global Forecast 2026-2032 - Product Image

Rifaximin Capsules Market - Global Forecast 2026-2032

  • Report
  • 183 Pages
  • Global
From
Rifaximin Tablets Market - Global Forecast 2026-2032 - Product Image

Rifaximin Tablets Market - Global Forecast 2026-2032

  • Report
  • 182 Pages
  • Global
From
Irritable Bowel Syndrome Treatment Market Size, Share, Trends and Forecast by Type, Product, Distribution Channel, and Region, 2026-2034 - Product Image

Irritable Bowel Syndrome Treatment Market Size, Share, Trends and Forecast by Type, Product, Distribution Channel, and Region, 2026-2034

  • Report
  • 148 Pages
  • Global
From
Irritable Bowel Syndrome (IBS) Treatment Market Report 2026 - Product Image

Irritable Bowel Syndrome (IBS) Treatment Market Report 2026

  • Report
  • 250 Pages
  • Global
From
Irritable Bowel Syndrome (IBS) Therapeutics - Global Strategic Business Report - Product Image

Irritable Bowel Syndrome (IBS) Therapeutics - Global Strategic Business Report

  • Report
  • 348 Pages
  • Global
From

About the Rifaximin Market

Rifaximin is a semi-synthetic antibiotic used to treat gastrointestinal diseases. It is used to treat travelers' diarrhea, irritable bowel syndrome with diarrhea, and hepatic encephalopathy. Rifaximin is also used to prevent recurrent episodes of hepatic encephalopathy. It is a broad-spectrum antibiotic that is effective against both Gram-positive and Gram-negative bacteria. Rifaximin is available in both oral and intravenous formulations. The oral formulation is available as tablets, capsules, and granules. The intravenous formulation is available as a solution for injection. Rifaximin is available in several countries, including the United States, Canada, and Europe. Rifaximin is a relatively new drug in the gastrointestinal drugs market. It is used to treat a variety of gastrointestinal diseases, and is becoming increasingly popular due to its effectiveness and safety profile. Some companies in the Rifaximin market include Salix Pharmaceuticals, Inc., Actavis, Inc., and Lupin Pharmaceuticals, Inc. Show Less Read more

Copyright © 2002-2026 Research and Markets. All Rights Reserved.